David Ricketts

Director, Business Development (CMO) @Etherna

eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases. We employ messenger RNA to unleash and boost a patient’s immune response against a tumor or infectious agent. eTheRNA builds on more than 30 years of mRNA manufacturing experience. Since 2018, all RNA production is performed in the brand new GMP authorized facility in Niel, Belgium. We now offer our expertise and capability to other parties interested in having their RNA manufactured according to their needs. We produce both non-GMP or research grade material and GMP grade material to be used in clinical trials